About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Slc2a4
solute carrier family 2 (facilitated glucose transporter), member 4
MGI:95758
58 phenotypes from 3 alleles in 11 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Slc2a4tm1Abel/Slc2a4+
Tg(Ckmm-cre)5Khn/0
involves: 129S4/SvJae * FVB 		decreased intestinal glucose absorption J:110773
decreased muscle cell glucose uptake J:110773
Slc2a4tm1Abel/Slc2a4tm1Abel
Tg(Ckmm-cre)5Khn/?
involves: 129/Sv * C57BL/6 		abnormal circulating glucose level J:75418
abnormal glucose tolerance J:75418
abnormal lipid homeostasis J:75418
abnormal lipid level J:75418
abnormal muscle physiology J:75418
decreased body weight J:75418
decreased fatty acids level J:75418
decreased skeletal muscle cell glucose uptake J:75418
decreased triglyceride level J:75418
hyperglycemia J:75418
increased liver glycogen level J:75418
insulin resistance J:75418
normal muscle phenotype J:75418
Slc2a4tm1Abel/Slc2a4tm1Abel
Tg(Ckmm-cre)5Khn/0
involves: 129S4/SvJae * FVB 		abnormal glucose homeostasis J:110773
abnormal lipid homeostasis J:110773
decreased adipocyte glucose uptake J:110773
decreased intestinal glucose absorption J:110773
decreased skeletal muscle cell glucose uptake J:110773
increased adipocyte glucose uptake J:110773
increased circulating glucose level J:110773
increased circulating insulin level J:110773
Slc2a4tm1Abel/Slc2a4tm1Abel
Tg(Fabp4-cre)1Abel/?
involves: 129S4/SvJae * FVB 		abnormal glucose homeostasis J:67292
abnormal glucose tolerance J:67292
abnormal glycogen homeostasis J:67292
insulin resistance J:67292
Slc2a4tm1Abel/Slc2a4tm1Abel
Tg(Myhca-cre)1Abel/?
involves: 129S4/SvJae * C57BL/6 * FVB 		abnormal cardiovascular system physiology J:108830
abnormal response to cardiac infarction J:108830
decreased cardiac muscle cell glucose uptake J:108830
decreased left ventricle systolic pressure J:108830
increased cardiac muscle cell glucose uptake J:108830
increased cardiac muscle glycogen level J:108830
Slc2a4tm1Abel/Slc2a4tm1Abel
Tg(Myhca-cre)1Abel/?
involves: 129S4/SvJae * FVB 		abnormal cardiovascular system physiology J:59054
abnormal glucose homeostasis J:59054
abnormal glucose tolerance J:59054
abnormal heart morphology J:59054
abnormal myocardium layer morphology J:59054
abnormal nervous system physiology J:59054
cardiac hypertrophy J:59054
decreased body weight J:59054
decreased cardiac muscle cell glucose uptake J:59054
increased heart weight J:59054
Slc2a4tm1Jdz/Slc2a4tm1Jdz
involves: 129S1/Sv * C57BL/6 		decreased adipocyte glucose uptake J:123335
decreased skeletal muscle cell glucose uptake J:123335
increased circulating glucose level J:123335
increased circulating insulin level J:123335
increased heart weight J:123335
Slc2a4tm1Jdz/Slc2a4tm1Jdz
Tg(ACTA1-cre)1Jdz/0
involves: 129S1/Sv * C57BL/6 * CBA 		cardiac hypertrophy J:123335
cardiac interstitial fibrosis J:123335
decreased adipocyte glucose uptake J:123335
decreased skeletal muscle cell glucose uptake J:123335
increased adipocyte glucose uptake J:123335
increased cardiac muscle cell glucose uptake J:123335
increased circulating glucose level J:123335
increased circulating insulin level J:123335
increased heart weight J:123335
increased skeletal muscle cell glucose uptake J:123335
thick ventricular wall J:123335
Slc2a4tm1Mch/Slc2a4+
involves: 129/Sv * C57BL/6 * SJL 		impaired glucose tolerance J:97234
increased insulin secretion J:97234
pancreatic islet hyperplasia J:97234
Slc2a4tm1Mch/Slc2a4+
involves: 129/Sv * C57BL/6J * CD-1 * SJL 		abnormal glucose homeostasis J:43935
abnormal glycogen homeostasis J:43935
cardiac hypertrophy J:43650
decreased muscle cell glucose uptake J:43935
decreased skeletal muscle cell glucose uptake J:43650
dystrophic cardiac calcinosis J:43650
heart inflammation J:43650
hepatic steatosis J:43650
normal homeostasis/metabolism phenotype J:43650, J:43935
hyperglycemia J:43650
hypertension J:43650
increased circulating insulin level J:43650, J:43935
increased fat cell size J:43650
insulin resistance J:43650, J:43935
macrovesicular hepatic steatosis J:43650
myocardium necrosis J:43650
Slc2a4tm1Mch/Slc2a4tm1Mch
involves: 129/Sv * C57BL/6 * C57BL/6J * CD-1 * SJL 		abnormal circulating glucose level J:49328
abnormal muscle physiology J:49328
cardiac hypertrophy J:49328
decreased circulating free fatty acids level J:49328
decreased circulating ketone body level J:49328
decreased gonadal fat pad weight J:49328
decreased total body fat amount J:49328
normal homeostasis/metabolism phenotype J:49328
increased circulating insulin level J:49328
increased heart weight J:49328
insulin resistance J:49328
postnatal growth retardation J:49328
premature death J:49328
Slc2a4tm1Mch/Slc2a4tm1Mch
involves: 129/Sv * C57BL/6 * C57BL/6J * SJL 		abnormal skeletal muscle fiber type ratio J:75600
cardiac hypertrophy J:75600
decreased body mass index J:75600
decreased skeletal muscle glycogen level J:75600
decreased skeletal muscle mass J:75600
impaired skeletal muscle contractility J:75600
increased muscle fatigability J:75600
Slc2a4tm1Mch/Slc2a4tm1Mch
involves: 129/Sv * C57BL/6J * SJL 		cardiac hypertrophy J:107849
cardiac interstitial fibrosis J:107849
thick ventricular wall J:107849
Slc2a4tm1Mch/Slc2a4tm1Mch
involves: C57BL/6 * CBA 		abnormal glucose homeostasis J:69914
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
10/29/2024
MGI 6.24 		The Jackson Laboratory